Back to News
Market Impact: 0.45
Viking's VK2735 Shows Strong Weight-Loss Maintenance With Less Frequent Dosing; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
Viking Therapeutics reported positive topline maintenance-study results for obesity candidate VK2735. Patients maintained most of their weight loss after transitioning from weekly administration to less frequent dosing, supporting the drug's potential convenience and long-term treatment profile.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
VKTX0.82
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Musk says Tesla to wind down polarising Cybertruck production as sales lag
- Tesla to wind down Cybertruck production at Texas factory next year to make room for Cybercab
- Ferrari’s Luce was ridiculed as a ‘Magic Mouse on wheels.’ Now the EV is sold out for 2027, and buyers haven’t even driven it yet
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs